# Durvalumab and Tremelimumab for Pediatric Malignancies

Source: https://onco.cc/trials/nct03837899/  
OnCo record `nct03837899` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Durvalumab and Tremelimumab in childhood cancers, run by AstraZeneca, active and no longer recruiting.

## Summary

Durvalumab and Tremelimumab for Pediatric Malignancies is a phase 1/2 interventional study registered as NCT03837899 by AstraZeneca, with 50 participants enrolled, started 2019-03-07 and due to reach its primary completion in 2023-02-28. Interventions recorded: Durvalumab / Tremelimumab Combination Therapy. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03837899
- Phase: 1/2
- Setting: Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or in Combination With Tremelimumab in Pediatric Patients With Advanced Solid Tumors and Hematological Malignancies.
- Sponsor: AstraZeneca
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT03837899: https://clinicaltrials.gov/study/NCT03837899

## Connected records

- cancers: [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct03837899.json